-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236

Benzinga·07/13/2026 11:57:19
Listen to the news
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.